BridgeMD
New treatment option for Parkinson's Disease (PD)
Official title Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
ClinicalTrials.gov ID: NCT07348250
What this study is testing
What is [18F]MK-0947?
[18F]MK-0947 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for parkinson's disease (pd).
Also referred to as MK-0947.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This clinical study is being conducted to learn more about a new imaging drug called [18F]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD). PD is a condition that affects movement, balance, and thinking.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80. Healthy volunteers may be eligible.
You may be able to join if
- Signed informed consent prior to any study procedures
- Women of childbearing potential: abstinent or use 2 contraception methods (one barrier) during study and 90 days post last injection
- Men: use 2 contraception methods and refrain from sperm donation during study and 90 days post last injection
- PD \& HE participants: Age 40-80 years; HP participants: Age 18-50 years
- Adequate circulation and normal clotting for arterial cannulation (if applicable)
You likely can't join if
- Unwilling or unable to provide informed consent
- Clinically significant hepatic, renal, cardiovascular, pulmonary, or systemic illness
- Pregnant or breastfeeding
- Contraindication to PET or MRI procedures (e.g., implants, claustrophobia)
- History of severe allergic reactions to PET tracers or related compounds
- Current or prior participation in investigational drug study within 30 days
See the full eligibility criteria
- Signed informed consent prior to any study procedures
- Women of childbearing potential: abstinent or use 2 contraception methods (one barrier) during study and 90 days post last injection
- Men: use 2 contraception methods and refrain from sperm donation during study and 90 days post last injection
- PD \& HE participants: Age 40-80 years; HP participants: Age 18-50 years
- Adequate circulation and normal clotting for arterial cannulation (if applicable)
- HE participants: no neurological disorder, no first-degree relative with idiopathic PD
- HP participants: healthy with no clinically relevant findings
- Unwilling or unable to provide informed consent
- Clinically significant hepatic, renal, cardiovascular, pulmonary, or systemic illness
- Pregnant or breastfeeding
- Contraindication to PET or MRI procedures (e.g., implants, claustrophobia)
- History of severe allergic reactions to PET tracers or related compounds
- Current or prior participation in investigational drug study within 30 days
- Any condition that may interfere with study conduct or participant safety
The study team makes the final eligibility decision.
Where it's taking place
- New Haven, Connecticut, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Haven, Connecticut, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.